Autolus Therapeutics (NASDAQ:AUTL) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note issued to investors on Friday, Benzinga reports. They currently have a $9.00 price objective on the stock.

Separately, Truist Financial boosted their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the company a buy rating in a report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics has an average rating of Moderate Buy and an average target price of $8.16.

Autolus Therapeutics Stock Down 2.4 %

NASDAQ AUTL opened at $4.90 on Friday. The firm has a market cap of $1.30 billion, a PE ratio of -4.12 and a beta of 1.90. Autolus Therapeutics has a 52 week low of $1.61 and a 52 week high of $7.45. The company has a 50 day moving average price of $6.01 and a 200 day moving average price of $5.06.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.18). On average, equities research analysts anticipate that Autolus Therapeutics will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC acquired a new position in Autolus Therapeutics during the third quarter worth $679,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $105,000. Exchange Traded Concepts LLC lifted its position in shares of Autolus Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company’s stock valued at $315,000 after acquiring an additional 12,387 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in Autolus Therapeutics by 17.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 286,065 shares of the company’s stock valued at $667,000 after purchasing an additional 41,524 shares during the last quarter. Finally, Lynx1 Capital Management LP purchased a new position in Autolus Therapeutics in the 3rd quarter valued at $3,176,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.